HLA-C mismatch is associated with inferior survival after unrelated donor non-myeloablative hematopoietic stem cell transplantation

Bone Marrow Transplantation
V T HoE P Alyea

Abstract

HLA-C matching is an important determinant of outcome after myeloablative unrelated donor (URD) hematopoietic stem cell transplantation. However, its importance in non-myeloablative stem cell transplantation (NST) is not known. We report a retrospective analysis of 111 patients who underwent URD NST, of whom 78 were 10/10 matched at HLA-A, B, C, DRB1, DQB1 and 33 were mismatched at one or more HLA-C antigen/allele (24 HLA-C only; nine HLA-C+other locus mismatch). Patients were conditioned with busulfan (0.8 mg/kg/day i.v. x 4 days) and fludarabine (30 mg/m(2)/day i.v. x 4 days). Graft-versus-host disease prophylaxis included cyclosporine/prednisone- or tacrolimus/mini-methotrexate-based regimens. HLA-C disparity did not impair engraftment. Median marrow donor chimerisms were >or=90% donor at day+30 and +100 in both groups. Overall survival at 2 years was 30% in HLA-C-mismatched and 51% in 10/10-matched patients (P=0.008). In Cox regression, HLA-C mismatch was an independent predictor of death (hazard ratio 1.85, P=0.04). Treatment-related mortality was higher in the HLA-C-mismatched group: 48 versus 16% (P=0.0001). Cumulative relapse incidence was 35% in the HLA-C-mismatched and 55% in the 10/10-matched cohort, P=0.09. HLA-C mi...Continue Reading

References

Dec 26, 2001·The New England Journal of Medicine·E W PetersdorfC Anasetti
Jul 15, 2004·Blood·Effie W PetersdorfJohn A Hansen

❮ Previous
Next ❯

Citations

Dec 15, 2010·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Simrit ParmarMarcos J de Lima
Mar 24, 2016·Seminars in Hematology·Henning Sebastian Schäfer, Jürgen Finke
Oct 11, 2008·Cancer Letters·Vijayakrishna K Gadi
May 28, 2008·Best Practice & Research. Clinical Haematology·Marcelo C Pasquini
Apr 24, 2007·Best Practice & Research. Clinical Haematology·Effie W Petersdorf
Jun 22, 2010·British Journal of Haematology·Bronwen E ShawJ Alejandro Madrigal
Jul 28, 2006·Current Opinion in Immunology·Effie W Petersdorf
Jun 10, 2015·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Michael R VernerisJohn Koreth
Mar 3, 2015·Bone Marrow Transplantation·R Reshef, D L Porter
Mar 17, 2009·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Nicolaus KrögerAxel Zander
May 20, 2009·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Hee-Je KimChun-Choo Kim
Jan 18, 2012·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Pavan ReddyJohn Koreth
Jan 16, 2007·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Karen K BallenJoseph H Antin
Jan 30, 2010·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Frédéric BaronYves Beguin
Jun 11, 2008·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Daniel WeisdorfJohn Klein
May 27, 2014·Frontiers in Immunology·Kirsten A ThusEric Spierings
Apr 5, 2011·The Korean Journal of Hematology·Meerim ParkJong Jin Seo
Aug 8, 2012·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·John KorethEdwin P Alyea

❮ Previous
Next ❯

Related Concepts

Related Feeds

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.